Tofacinix 5 mg contains Tofacitinib, an orally active Janus kinase (JAK) inhibitor used in the management of several autoimmune and inflammatory conditions. Tofacitinib works by selectively inhibiting JAK enzymes, which play a central role in the signaling pathways of cytokines and growth factors that regulate immune responses. By modulating these pathways, Tofacinix helps reduce inflammation, immune-mediated tissue damage, and disease activity in chronic autoimmune disorders.

Tofacitinib has transformed the treatment landscape for patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ulcerative colitis (UC), especially in cases where conventional therapies, such as methotrexate or biologics, are insufficient or poorly tolerated. Its oral administration provides a convenient alternative to injectable therapies while maintaining high efficacy and safety profiles.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Tofacinix 5 mg is indicated for:

• Rheumatoid arthritis (RA): For adult patients with moderate to severe RA who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).

• Psoriatic arthritis (PsA): For adults with active PsA who have responded inadequately to conventional therapy.

• Ulcerative colitis (UC): For adults with moderate to severe active UC who have not responded adequately to conventional treatments, including corticosteroids or immunosuppressants.

Therapeutic Class

• Janus Kinase (JAK) Inhibitor

• Immunomodulator / Antirheumatic Agent

Pharmacology

Tofacitinib inhibits JAK1 and JAK3, and to a lesser extent JAK2, blocking the signaling pathways of multiple pro-inflammatory cytokines involved in autoimmune disease pathogenesis. By interfering with these signals, Tofacinix reduces immune cell activation, inflammatory cytokine production, and tissue damage, helping to control disease progression.

The drug is rapidly absorbed following oral administration, with steady-state concentrations typically achieved within a few days of consistent dosing. It undergoes hepatic metabolism primarily via CYP3A4 and excretion through both renal and fecal routes.

Dosage and Administration

• The recommended dose for Tofacinix is 5 mg twice daily for most indications, but dosing may vary depending on disease type, severity, and patient response.

• It can be taken orally with or without food.

• Dose adjustments may be required in patients with renal or hepatic impairment or those taking interacting medications.

• Regular monitoring of blood counts, liver function, and lipid profiles is essential during therapy.

Key Benefits

• Effective in controlling symptoms and disease progression in RA, PsA, and UC.

• Oral administration for patient convenience.

• Rapid onset of action with noticeable improvement in symptoms within weeks.

• Can be used as monotherapy or in combination with other disease-modifying treatments.

Precautions and Warnings

• Increased risk of infections, including serious and opportunistic infections, due to immune modulation.

• Regular monitoring for tuberculosis, hepatitis B/C, and other latent infections is recommended before starting therapy.

• Use with caution in patients with a history of malignancy, thrombosis, or cardiovascular disease.

• Not recommended during pregnancy or breastfeeding unless clearly necessary.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Adverse Effects

Common adverse effects include upper respiratory tract infections, headache, diarrhea, nausea, and increased cholesterol levels. Less commonly, serious infections, cytopenias, liver enzyme elevations, and thromboembolic events may occur. Most side effects are manageable under medical supervision.

Storage

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.

Tofacinix 5 mg offers an effective, convenient oral therapy for autoimmune and inflammatory conditions, providing significant symptom relief, improved quality of life, and disease control in patients with chronic immune-mediated disorders.